CA
NZ
UK
AU
IND
US
• The pullback follows a remarkable year-to-date surge of over 144%.
• CLVT shares closed up 16.67% today at $2.59, ranking among the top weekly performers tracked by Morningstar.
• Three Companies Face Compliance Challenges Simultaneously: Mdxhealth received a deficiency notice, NewGenIvf announced a reverse split, and Tenon Medical raised dilutive capital despite positive FDA clearance, all on the same day.
• Strategic IP Milestone: Galmed Pharmaceuticals' (NASDAQ: GLMD) USPTO Notice of Allowance strengthens the company's negotiating position in future licensing talks.
• Non-Negotiable Regulatory Step: Biocompatibility testing under ISO 10993 is a required prerequisite before FDA submission for devices like NASARIX.
• Acceptable Safety Profile Confirmed at ASCO: Phase 3 safety data presented at ASCO demonstrated acceptable safety across all combination cohorts with no new safety signals identified.
• Major Price Target Increase: Chardan Capital raised its EyePoint Pharmaceuticals (NASDAQ: EYPT) target to $65 from $29, a 124% jump, while maintaining a Buy rating.
• Muscle Metabolism Is a Growing Drug Target: ANT1 modulation addresses mitochondrial energy function in muscle — relevant across sarcopenia, myopathy, and chronic disease-related muscle weakness.
• Phase 1/2 Trial Initiated July 2, 2026: Molecular Partners initiated the Phase 1/2 trial for [212Pb]Pb-MP0712 on July 2, 2026, targeting DLL3-positive SCLC and other neuroendocrine tumors.
• Early Proof of Concept: PMGC Holdings' (NASDAQ: ELAB) 50% peak improvement in ANT1 expression offers an initial signal for its AI-driven discovery approach.
Please wait processing your request...